IDH3A and glioma: Mutations of the key Krebs cycle enzyme isocitrate dehydrogenase (IDH) are considered to be vital for the genesis of low-grade gliomas and secondary glioblastomas [5], prompting the World Health Organization (WHO) to separate gliomas according to IDH mutation status into IDH mutant and IDH wild-type (IDH1wt) entities in the “2016 WHO Classification of Tumors of the Central Nervous System” [6].